NasdaqGS:XRAY

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

DENTSPLY SIRONA Inc. designs, develops, manufactures, and markets various dental products and technologies, and other consumable dental products and equipment primarily for the professional dental market worldwide.


Snowflake Analysis

Excellent balance sheet and fair value.


Similar Companies

Share Price & News

How has DENTSPLY SIRONA's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XRAY has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-4.4%

XRAY

-0.2%

US Medical Equipment

3.0%

US Market


1 Year Return

-17.4%

XRAY

14.8%

US Medical Equipment

15.8%

US Market

Return vs Industry: XRAY underperformed the US Medical Equipment industry which returned 16.8% over the past year.

Return vs Market: XRAY underperformed the US Market which returned 15.4% over the past year.


Shareholder returns

XRAYIndustryMarket
7 Day-4.4%-0.2%3.0%
30 Day-0.3%8.5%6.0%
90 Day6.4%10.7%16.4%
1 Year-16.7%-17.4%15.8%14.8%18.4%15.8%
3 Year-20.2%-22.1%75.5%70.7%44.8%35.4%
5 Year-21.5%-24.1%118.0%101.1%75.7%56.7%

Price Volatility Vs. Market

How volatile is DENTSPLY SIRONA's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is DENTSPLY SIRONA undervalued compared to its fair value and its price relative to the market?

48.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: XRAY ($43.26) is trading below our estimate of fair value ($83.38)

Significantly Below Fair Value: XRAY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: XRAY is poor value based on its PE Ratio (114.9x) compared to the US Medical Equipment industry average (54.5x).

PE vs Market: XRAY is poor value based on its PE Ratio (114.9x) compared to the US market (18.5x).


Price to Earnings Growth Ratio

PEG Ratio: XRAY is poor value based on its PEG Ratio (1.6x)


Price to Book Ratio

PB vs Industry: XRAY is good value based on its PB Ratio (2x) compared to the US Medical Equipment industry average (4.2x).


Next Steps

Future Growth

How is DENTSPLY SIRONA forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

71.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XRAY's forecast earnings growth (71.4% per year) is above the savings rate (2.2%).

Earnings vs Market: XRAY's earnings (71.4% per year) are forecast to grow faster than the US market (22.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: XRAY's revenue (8% per year) is forecast to grow slower than the US market (9.4% per year).

High Growth Revenue: XRAY's revenue (8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: XRAY's Return on Equity is forecast to be low in 3 years time (10.3%).


Next Steps

Past Performance

How has DENTSPLY SIRONA performed over the past 5 years?

-28.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XRAY has a large one-off loss of $383.7M impacting its June 30 2020 financial results.

Growing Profit Margin: XRAY became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: XRAY has become profitable over the past 5 years, growing earnings by -28.8% per year.

Accelerating Growth: XRAY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: XRAY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.2%).


Return on Equity

High ROE: XRAY's Return on Equity (1.8%) is considered low.


Next Steps

Financial Health

How is DENTSPLY SIRONA's financial position?


Financial Position Analysis

Short Term Liabilities: XRAY's short term assets ($1.8B) exceed its short term liabilities ($891.5M).

Long Term Liabilities: XRAY's short term assets ($1.8B) do not cover its long term liabilities ($2.5B).


Debt to Equity History and Analysis

Debt Level: XRAY's debt to equity ratio (30.7%) is considered satisfactory.

Reducing Debt: XRAY's debt to equity ratio has reduced from 60.9% to 30.7% over the past 5 years.

Debt Coverage: XRAY's debt is well covered by operating cash flow (41.2%).

Interest Coverage: XRAY's interest payments on its debt are well covered by EBIT (20.5x coverage).


Balance Sheet


Next Steps

Dividend

What is DENTSPLY SIRONA current dividend yield, its reliability and sustainability?

0.92%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: XRAY's dividend (0.92%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.65%).

High Dividend: XRAY's dividend (0.92%) is low compared to the top 25% of dividend payers in the US market (4.45%).


Stability and Growth of Payments

Stable Dividend: XRAY's dividends per share have been stable in the past 10 years.

Growing Dividend: XRAY's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (102.9%), XRAY's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: XRAY's dividends in 3 years are forecast to be thoroughly covered by earnings (14.6% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Don Casey (60 yo)

2.5yrs

Tenure

US$11,366,243

Compensation

Mr. Donald M. Casey, Jr., also known as Don, serves as CEO and Director at DENTSPLY International Inc., since 2018. Mr. Casey has been Chief Executive Officer and a Director at Dentsply Sirona Inc. since ...


CEO Compensation Analysis

Compensation vs Market: Don's total compensation ($USD11.37M) is above average for companies of similar size in the US market ($USD7.33M).

Compensation vs Earnings: Don's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Donald Casey
CEO & Director2.5yrsUS$11.37m0.045%
$ 4.2m
Jorge Gomez
Executive VP & CFO1yrUS$10.30m0.0099%
$ 942.1k
Keith Ebling
Executive VP2.83yrsUS$4.61m0.0076%
$ 715.5k
Walter Petersohn
Senior VP & Chief Commercial Officer3.08yrsUS$3.11m0.021%
$ 1.9m
Cord Staehler
Senior VP & Chief Technology Officer1.25yrsno data0.0018%
$ 165.9k
John Sweeney
Vice President of Investor Relationsno datano datano data
Lisa Yankie
Senior VP and Chief HR Officer & Communications0.83yrno data0.0017%
$ 159.2k
Chidam Chidambaram
Senior VP1.25yrsno data0.0051%
$ 480.5k
Albert Sterkenburg
Senior Vice President11.58yrsUS$1.35mno data
Teresa Dolan
Chief Clinical Officer & VPno datano datano data
Markus Boehringer
Senior Vice President of EMEA RCO3.08yrsUS$1.52m0.012%
$ 1.1m
Matthew Coggin
Senior VP of Business Development & Strategy Officer1.25yrsno data0.0082%
$ 780.9k

1.9yrs

Average Tenure

52.5yo

Average Age

Experienced Management: XRAY's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Donald Casey
CEO & Director2.5yrsUS$11.37m0.045%
$ 4.2m
Francis Lunger
Independent Director15.25yrsUS$326.95k0.012%
$ 1.1m
Eric Brandt
Independent Non-Executive Chairman2.92yrsUS$517.03k0.013%
$ 1.2m
Harry M. Kraemer
Independent Director4.5yrsUS$278.57k0.059%
$ 5.5m
Betsy Holden
Independent Director2.58yrsUS$321.32k0.0042%
$ 400.9k
Michael Alfano
Independent Director19.5yrsUS$271.25k0.0050%
$ 472.0k
Leslie Varon
Independent Director2.58yrsUS$278.75kno data
Gregory Lucier
Independent Director1.25yrsUS$256.42k0.0061%
$ 576.2k
Arthur Kowaloff
Independent Director4.5yrsUS$267.50k0.019%
$ 1.8m
William Deese
Independent Director9.5yrsUS$283.75k0.0069%
$ 656.8k
Janet Vergis
Independent Director0.92yrUS$162.13kno data

2.9yrs

Average Tenure

64yo

Average Age

Experienced Board: XRAY's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: XRAY insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

DENTSPLY SIRONA Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DENTSPLY SIRONA Inc.
  • Ticker: XRAY
  • Exchange: NasdaqGS
  • Founded: 1899
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$9.477b
  • Shares outstanding: 219.08m
  • Website: https://www.dentsplysirona.com

Number of Employees


Location

  • DENTSPLY SIRONA Inc.
  • 13320 Ballantyne Corporate Place
  • Charlotte
  • North Carolina
  • 28277-3607
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XRAYNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 1987
DY2DB (Deutsche Boerse AG)YesCommon StockDEEURAug 1987
0I8FLSE (London Stock Exchange)YesCommon StockGBUSDAug 1987
XRAYWBAG (Wiener Boerse AG)YesCommon StockATEURAug 1987
DY2ETLX (Eurotlx)YesCommon StockITEURAug 1987
XRAY34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH REP 1 COM USD0.01BRBRLMay 2019

Biography

DENTSPLY SIRONA Inc. designs, develops, manufactures, and markets various dental products and technologies, and other consumable dental products and equipment primarily for the professional dental market w ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/06 23:45
End of Day Share Price2020/08/06 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.